<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35276385</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-264X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>214</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmaceutical and biomedical analysis</Title>
          <ISOAbbreviation>J Pharm Biomed Anal</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.</ArticleTitle>
        <Pagination>
          <StartPage>114693</StartPage>
          <MedlinePgn>114693</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpba.2022.114693</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0731-7085(22)00114-5</ELocationID>
        <Abstract>
          <AbstractText>Antiviral drugs have gained much more attention in recent years due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and many drug candidates are currently under investigation in order to end pandemic. Molnupiravir, a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, is one of the promising candidates for SARS-CoV-2 treatment. In this study, a RP-HPLC method was developed for the determination of Molnupiravir and applied for in vitro permeability studies of self-emulsifying drug delivery system (SEDDS) formulations using Caco-2 cell line. Discovery® HS C18 Column (75 ×4.6 mm, 3 µm) was used at 30 °C. Isocratic elution was performed with ACN:water (20:80 v/v) mixture. The flow rate was 0.5 mL/min and UV detection was at 240 nm. Molnupiravir eluted within 5 min. Molnupiravir was exposed to thermal, photolytic, hydrolytic, and oxidative stress conditions. Peak homogeneity data of Molnupiravir in the stressed samples peak obtained using photodiode array detector, in the stressed sample chromatograms, demonstrated the specificity of the method for their estimation in presence of degradants. The developed method was validated according to the International Council for Harmonisation (ICH) guidelines and found to be linear within the range 0.1-60.0 μg/mL. The method was simple, rapid, selective, sensitive, accurate, precise, robust and rugged. Thus, it was applied successfully for permeability quantitation of Molnupiravir in nanoformulations. The apparent permeability of Molnupiravir in SEDDS formulations, which have droplet size under 350 nm, was calculated as 3.20 ± 0.44 × 10<sup>-6</sup> cm/s.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Reçber</LastName>
            <ForeName>Tuba</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, 06100 Sıhhiye, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Timur</LastName>
            <ForeName>Selin Seda</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06100 Sıhhiye, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erdoğan Kablan</LastName>
            <ForeName>Sevilay</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, 06100 Sıhhiye, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yalçın</LastName>
            <ForeName>Fatma</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Tobio Novelfarma Drug Industry and Trade Limited Company, 34768 Ümraniye, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karabulut</LastName>
            <ForeName>Tutku Ceren</ForeName>
            <Initials>TC</Initials>
            <AffiliationInfo>
              <Affiliation>Tobio Novelfarma Drug Industry and Trade Limited Company, 34768 Ümraniye, Istanbul, Turkey; Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06100 Tandoğan, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neslihan Gürsoy</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06100 Sıhhiye, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eroğlu</LastName>
            <ForeName>Hakan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06100 Sıhhiye, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kır</LastName>
            <ForeName>Sedef</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, 06100 Sıhhiye, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nemutlu</LastName>
            <ForeName>Emirhan</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, 06100 Sıhhiye, Ankara, Turkey. Electronic address: enemutlu@hacettepe.edu.tr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Pharm Biomed Anal</MedlineTA>
        <NlmUniqueID>8309336</NlmUniqueID>
        <ISSNLinking>0731-7085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018938" MajorTopicYN="N">Caco-2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Molnupiravir</Keyword>
        <Keyword MajorTopicYN="N">Optimization</Keyword>
        <Keyword MajorTopicYN="N">Permeability</Keyword>
        <Keyword MajorTopicYN="N">RP-HPLC</Keyword>
        <Keyword MajorTopicYN="N">Validation</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35276385</ArticleId>
        <ArticleId IdType="pmc">PMC8881887</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jpba.2022.114693</ArticleId>
        <ArticleId IdType="pii">S0731-7085(22)00114-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>2022. 〈https://covid19.who.int/measures〉. (Accessed 10 Jaunary 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Natchus M.G., Cohen O., Holman W., Painter W.P. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr. Opin. Virol. 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.-J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11(515)</Citation>
        </Reference>
        <Reference>
          <Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021;297(1)</Citation>
        </Reference>
        <Reference>
          <Citation>Painter W.P., Holman W., Bush J.A., Almazedi F., Malik H., Eraut N.C., Morin M.J., Szewczyk L.J., Painter G.R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 2021;65(5) e02428-20.</Citation>
        </Reference>
        <Reference>
          <Citation>Soyseven M., Kaynak M.S., Çelebier M., Aboul-Enein H.Y., Arli G. Development of a RP-HPLC method for simultaneous determination of reference markers used for in-situ rat intestinal permeability studies. J. Chromatogr. B. 2020;1147</Citation>
        </Reference>
        <Reference>
          <Citation>EMA, ICH M9 Guideline on Biopharmaceutics Classification System-based Biowaivers, in: C.f.M.P.f.H. Use (Ed.), 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>FDA, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, in: U.S.D.o.H.a.H.S.F.a.D.A.C.f.D.E.a.R. (CDER) (Ed.), 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Buckley S.T., Fischer S.M., Fricker G., Brandl M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 2012;45(3):235–250.</Citation>
        </Reference>
        <Reference>
          <Citation>Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 2001;46(1–3):27–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11259831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 2005;21(1):1–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15868485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O. McPolin, An introduction to HPLC for pharmaceutical analysis, Lulu.com, Mourine Training Services, Northern, Ireland, UK, 2009.</Citation>
        </Reference>
        <Reference>
          <Citation>Amara A., Penchala S.D., Else L., Hale C., FitzGerald R., Walker L., Lyons R., Fletcher T., Khoo S. The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva. J. Pharm. Biomed. Anal. 2021;206</Citation>
        </Reference>
        <Reference>
          <Citation>I.H.T. Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1) 1(20) (2005), 5.</Citation>
        </Reference>
        <Reference>
          <Citation>Timur S.S., Yoyen-Ermis D., Esendagli G., Yonat S., Horzum U., Esendagli G., Gursoy R.N. Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer. Eur. J. Pharm. Biopharm. Off. J. Arb. Pharm. Verfahr. 2019;136:138–146.</Citation>
        </Reference>
        <Reference>
          <Citation>Gursoy R.N., Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. = Biomed. Pharmacother. 2004;58(3):173–182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15082340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ICH Harmonised Tripartite Guideline, Validationof analytical procedures: text and methodology, Q2 (R1) 1(20) (2005), 5.</Citation>
        </Reference>
        <Reference>
          <Citation>Zur M., Gasparini M., Wolk O., Amidon G.L., Dahan A. The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Mol. Pharm. 2014;11(5):1707–1714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24735251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berginc K., Sibinovska N., Zakelj S., Trontelj J., Legen I. Biopharmaceutical classification of desloratadine - not all drugs are classified the easy way. Acta Pharm. 2020;70(2):131–144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31955139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.S., Mitchell S., Kijek P., Tsume Y., Hilfinger J., Amidon G.L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol. Pharm. 2006;3(6):686–694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17140256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Incecayir T., Tsume Y., Amidon G.L. Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol. Pharm. 2013;10(3):958–966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3605724</ArticleId>
            <ArticleId IdType="pubmed">23327720</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
